Skip to main content

Table 1 Dose de-escalation schema of mycophenolate mofetil

From: Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial

Dose level Dose of mycophenolate mofetil in adult patients
0 (initial dose) 5 g/day (5 tablets twice a day)
-1 4 g/day (4 tablets twice a day)
−2 3 g/day (3 tablets twice a day)
−3 2 g/day (2 tablets twice a day)
−4 1 g/day (1 tablet twice a day)
  1. Note that the initial dose (dose level 0) of mycophenolate mofetil in pediatric patients is the dose that is adjusted based on the patients’ BSA at enrollment; dose level –x in pediatric patients will be the initial dose–x g/day